Adjuvant therapy after surgery for high-risk bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Pathologically confirmed intrahepatic cholangiocarcinoma (cancer confirmed by tissue sample) within 12 weeks after surgical removal
- At least one high-risk feature such as tumor breaking through the liver capsule, multiple tumors, a single tumor larger than 5 cm, blood vessel invasion, or lymph node spread
- No prior chemotherapy, immunotherapy, or systemic cancer treatment
- Good overall health (ECOG score 0–2) and expected to live at least 3 months
- Adequate liver, kidney, and blood function
- Willingness to use effective birth control during the study and for 4 months after the last treatment dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
This study tests a combination of two drugs (apatinib and adebrelimab) with standard chemotherapy for people with bile duct cancer that cannot be removed surgically. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a new combination of drugs for people with advanced bile duct cancer that cannot be removed by surgery. Combining immunotherapy with chemotherapy may help shrink tumors and slow the cancer's growth.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed procedure (like chemoembolization) versus a standard chemotherapy cocktail for a type of bile duct cancer that is confined to the liver. It aims to see if the new combo can help patients live longer or slow the cancer down.
This trial tests a new drug combination—cisplatin, gemcitabine (standard chemotherapy), and rilvegostomig (an immunotherapy)—given before and after surgery for a specific type of liver cancer called intrahepatic cholangiocarcinoma. The goal is to reduce the chance of the cancer coming back after surgery.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.